135 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28109791	44	Identification of a selective inhibitor of transforming growth factorß-activated kinase 1 by biosensor-based screening of focused libraries.	Chugai Pharmaceutical
28094183	25	Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors.	Oribase Pharma
28082036	23	Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate.	Takeda California
27994735	163	Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors.	University of North Carolina At Chapel Hill
27299736	37	The"Cyclopropyl Fragment" is a Versatile Player that Frequently Appears in Preclinical/Clinical Drug Molecules.	St. John'S University
27131066	36	An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.	Chinese Academy of Sciences
27288183	130	Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.	Southeast University
26555154	36	AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.	University of Edinburgh
27061987	40	Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.	Chinese Academy of Sciences (Cas)
26951753	336	Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.	Novartis Institutes For Biomedical Research
26717201	68	Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.	Shenyang Pharmaceutical University
26698536	56	Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.	Chinese Academy of Sciences
26762835	342	Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).	Icahn School of Medicine At Mount Sinai
26342867	52	Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.	Sichuan University
26005523	37	Design, Synthesis, and Biological Evaluation of Novel Imidazo[1,2-a]pyridine Derivatives as Potent c-Met Inhibitors.	Shanghai Institute of Materia Medica
25835317	63	Design, Synthesis, and Structure-Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer.	Sichuan University
25827399	52	Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis.	Chinese Academy of Sciences
25633741	67	Discovery and profiling of a selective and efficacious Syk inhibitor.	Novartis Institutes For Biomedical Research
25068800	34	UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor.	University of North Carolina At Chapel Hill
24785465	80	Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.	Chinese Academy of Sciences
24904961	27	Synthesis and in vivo SAR study of indolin-2-one-based multi-targeted inhibitors as potential anticancer agents.	Qilu Pharmaceutical
24479418	39	Cytotoxic and protein kinase inhibiting nakijiquinones and nakijiquinols from the sponge Dactylospongia metachromia.	Heinrich Heine Universit£T
24328302	94	Protein kinase and HDAC inhibitors from the endophytic fungus Epicoccum nigrum.	Heinrich-Heine-Universit£T D£Sseldorf
24219778	139	Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis.	Eshelman School of Pharmacy�Department of Pharmacology�Lineberger Compreh
24195762	135	Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors.	University of North Carolina At Chapel Hill
24900750	14	Aminopyridyl/Pyrazinyl Spiro[indoline-3,4'-piperidine]-2-ones As Highly Selective and Efficacious c-Met/ALK Inhibitors.	Southern Medical University
24157370	22	The sulfamide moiety affords higher inhibitory activity and oral bioavailability to a series of coumarin dual selective RAF/MEK inhibitors.	Chugai Pharmaceutical
23993328	41	Synthesis and biological evaluation of 2-amino-5-aryl-3-benzylthiopyridine scaffold based potent c-Met inhibitors.	Chinese Academy of Sciences
22749189	24	Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation.	Institut Curie
23394126	170	Discovery of a novel class of highly potent, selective, ATP-competitive, and orally bioavailable inhibitors of the mammalian target of rapamycin (mTOR).	Exelixis
23312472	129	Highly selective 2,4-diaminopyrimidine-5-carboxamide inhibitors of Sky kinase.	Pfizer
22932313	9	Design and synthesis of diarylamines and diarylethers as cytotoxic antitumor agents.	Beijing Institute of Pharmacology & Toxicology
22827572	67	Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK).	Glaxosmithkline
22734674	81	The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.	Amgen
22039836	188	Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141).	Johnson & Johnson Pharmaceutical Research & Development
22863529	31	Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.	Chinese Academy of Sciences
22662287	116	Discovery of Novel Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia.	TBA
22247788	40	Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.	TBA
24900361	27	Exploring aigialomycin d and its analogues as protein kinase inhibitors for cancer targets.	TBA
18183025	12060	A quantitative analysis of kinase inhibitor selectivity.	Ambit Biosciences
18077425	197	Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.	Harvard Medical School
18342505	43	Design and synthesis of a pyrido[2,3-d]pyrimidin-5-one class of anti-inflammatory FMS inhibitors.	Johnson & Johnson Pharmaceutical Research & Development
16876403	85	Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure.	Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
22221201	32	VX-322: a novel dual receptor tyrosine kinase inhibitor for the treatment of acute myelogenous leukemia.	University of Kentucky
22269278	50	Angiogenesis inhibitors identified by cell-based high-throughput screening: synthesis, structure-activity relationships and biological evaluation of 3-[(E)-styryl]benzamides that specifically inhibit endothelial cell proliferation.	Chugai Pharmaceutical
22136433	67	7,8-dichloro-1-oxo-ß-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes.	Ludwig-Maximilians University of Munich
22119469	107	Novel and selective spiroindoline-based inhibitors of Sky kinase.	Pfizer
22014550	337	Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).	Ansaris
21982797	128	9,10-secosteroids, protein kinase inhibitors from the Chinese gorgonian Astrogorgia sp.	Peking University
22037378	31824	Comprehensive analysis of kinase inhibitor selectivity.	Ambit Biosciences
21936542	143	Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase.	Novartis Institute For Biomedical Research
21812414	106	Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).	Pfizer
21741249	32	Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp.	Heinrich Heine Universit£T
24900250	81	Kinase Inhibition by Deoxy Analogues of the Resorcylic Lactone L-783277	TBA
19654408	2521	AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).	Ambit Biosciences
19039322	50	Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.	Center For Molecular Medicine of The Austrian Academy of Sciences
20093027	92	Discovery of 6-benzyloxyquinolines as c-Met selective kinase inhibitors.	Chugai Pharmaceutical
19053831	39	Search for inhibitors of bacterial and human protein kinases among derivatives of diazepines[1,4] annelated with maleimide and indole cycles.	Institute of General Genetics
19035792	85	Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.	Glaxosmithkline
18248988	16	Entry into a new class of protein kinase inhibitors by pseudo ring design.	Novartis Institutes For Biomedical Research
18242992	30	Discovery of novel FMS kinase inhibitors as anti-inflammatory agents.	Johnson & Johnson Pharmaceutical Research & Development
16934458	124	Identification of isothiazole-4-carboxamidines derivatives as a novel class of allosteric MEK1 inhibitors.	Valeant Pharmaceuticals Research & Development
31757666	314	Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.	Merck
27448775	102	Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.	Shanghai Pharmaceuticals Holding
27379978	140	4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors.	Chinese Academy of Sciences
30685094	22	Discovery of a potent tyrosine kinase AXL inhibitor bearing the 3-((2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)amino)pyrazine core.	Shanghai University
31693351	473	Discovery of 4	TBA
31677447	44	Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold.	Central China Normal University
29928803	92	Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors.	Vichem Chemie Research
31207462	42	Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade.	Sichuan Academy of Medical Science & Sichuan Provincial People'S Hospital
30987781	88	Novel 7-formyl-naphthyridyl-ureas derivatives as potential selective FGFR4 inhibitors: Design, synthesis, and biological activity studies.	Southeast University
30503936	10	Discovery of N	Zhuhai Campus of Zunyi Medical University
30188734	41	Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.	University of Arkansas For Medical Sciences
30384048	365	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.	University of Florida
30340900	37	Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors.	Korea University
31526603	379	Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.	Takeda Pharmaceutical
30347155	155	Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group.	Unc Eshelman School of Pharmacy
30170943	35	Design and synthesis of potent RSK inhibitors.	Novartis Institutes For Biomedical Research
30309671	12	Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.	Psl Research University
30480444	85	Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.	Sichuan University/Collaborative Innovation Center of Biotherapy
29466002	193	Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening.	University of Edinburgh
29407963	47	Identification of novel N	Zhuhai Campus of Zunyi Medical University
28755635	25	Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors.	China Pharmaceutical University
28929759	83	Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease.	Wuxi Apptec
28711351	74	Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy.	Rigel Pharmaceuticals
28460311	8	The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3? inhibitors for the treatment of ovarian cancer.	Fudan University
28411455	45	Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.	Shanghai Pharmaceuticals Holding
28714692	232	Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.	University of Chinese Academy of Sciences
11714892	4	N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-nitrophenyl) cyclohexanecarboxamide: a novel pre- and postsynaptic 5-hydroxytryptamine(1A) receptor antagonist active on the lower urinary tract.	Recordati
11408556	2	Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.	Astrazeneca Pharmaceuticals
17512966	4	Structure-based discovery of a new class of Bcl-xL antagonists.	Burnham Institute For Medical Research
9650799	159	[125I]Tyr10-cortistatin14 labels all five somatostatin receptors.	Novartis Pharma
19270684	3	Transition state analogs of 5'-methylthioadenosine nucleosidase disrupt quorum sensing.	Albert Einstein College of Medicine
18370373	48	A novel series of potent and selective ketone histone deacetylase inhibitors with antitumor activity in vivo.	Irbm/Merck Research Laboratories
16439135	24	Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases.	Kyushu Institute of Technology
15916442	52	Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles.	Wyeth Research
11728184	20	Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.	Biocryst Pharmaceuticals